What is Kaleido?
Founded in 2013 and headquartered in Utrecht, Netherlands, Kaleido specializes in the manufacturing of advanced insulin pumps. The company operates within the critical healthcare technology sector, addressing the needs of individuals managing diabetes. By focusing on user-centric design and technological innovation, Kaleido aims to improve the quality of life for its patients through reliable and effective insulin delivery systems. The company's commitment to this specialized medical device market positions it as a key player in the ongoing evolution of diabetes care solutions.
How much funding has Kaleido raised?
Kaleido has raised a total of $85.3M across 2 funding rounds:
Series B
$11.3M
Series C
$74M
Series B (1970): $11.3M, investors not publicly disclosed
Series C (2021): $74M led by INKEF Capital, Partners in Equity, Health Innovations, and Life Sciences Partners
Key Investors in Kaleido
INKEF Capital
INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative technology companies. INKEF Capital was founded in 2010 by Dutch pension fund ABP and with €500 million under management is one of the largest venture capital funds in the Netherlands. INKEF focuses on investment opportunities in Healthcare, Technology, IT/New Media & FinTech.
Partners in Equity
Partners in Equity is a private investment firm dedicated to supporting companies and funds that address environmental challenges. The firm focuses on sustainable agriculture, circularity, and climate solutions, aiming to create a more inclusive and sustainable future. With a commitment to long-term partnerships, they invest in later-stage growth companies primarily in Europe, while maintaining a global outlook. Their holistic approach ensures that financial returns are aligned with positive social and environmental impact.
Life Sciences Partners
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
What's next for Kaleido?
The substantial enterprise-level capital infusion indicates Kaleido is poised for significant scaling and further product development. This strategic investment is likely to accelerate manufacturing capabilities, expand market reach, and potentially fund research into next-generation insulin pump technologies. With a clear focus on innovation and a growing market need, Kaleido is well-positioned to enhance its competitive standing and solidify its role in advancing diabetes management.
See full Kaleido company page
